secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001193125-24-162653
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum expands board to 9, elects Colin Hill; stockholders elect directors, ratify auditor
--------------------------------------------------------------------------------

- Board expanded from 8 to 9; Colin Hill elected Class I director, term expiring at 2026 annual meeting.
- Hill received automatic grant of 60,000 nonqualified stock options at $7.00/share.
- Annual meeting: James Collins, James Geraghty, Alex Sapir elected as Class II directors for 3-year term.
- Stockholders ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312524162653/0001193125-24-162653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312524162653/d845947d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-162653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer